Freyja Healthcare Secures $8M in New Funding and Appoints Tracy MacNeal as Independent Board Director

Freyja Healthcare, based in Boston, has secured $8 million in new funding to accelerate the development and commercialization of its product line. At the forefront is the VereSee™ device, a 2mm abdominal access video entry device for laparoscopic surgery. This funding round brings Freyja's total raised capital to over $17 million from key investors in healthcare technology.

Founded in 2017, Freyja specializes in women's health and has rapidly advanced with four products in development and a significant portfolio of 17 granted patents. Dr. Jón Ívar Einarsson, interim CEO, emphasized the company's commitment to enhancing R&D capabilities and preparing for commercialization.

Tracy MacNeal, CEO of Materna Medical, joins Freyja's board to lend her expertise to the company. Women's health is a fast-growing industry, estimated to reach $60 billion by 2027, with women making most healthcare decisions and spending more per capita than men.

The recent financing complements Freyja's achievements, such as the 510(k) clearance for the VereSee System in May 2024. Freyja plans for the initial commercialization of VereSee in the second half of 2024.